PTCT

PTC Therapeutics, Inc.

Phase 3 Confirmed

votoplam

Huntington's disease

Resolved

70days ago

Phase 3 readout · Apr 28, 2026

What's at stake Phase 3 trial results for votoplam in Huntington's disease are due Apr 28, 2026. A clean hit validates the program; a miss can gap the stock down hard.

Primary source · SEC 8-K verified 13h ago

“PTC Therapeutics Reports Positive Topline Results from Month 24 Interim Analysis of PIVOT-HD Extension Study of Votoplam”

Add to calendar Post on X Reddit

Provenance